I read with interest the news on evolocumab and a large international trial on 27,000 patients.
The British Heart Foundation said the findings were a significant advance in fighting the biggest killer in the world.
The study found that for every 74 people who took the drug for two years, one heart attack or stroke would be prevented. However, the findings, published in the New England Journal of Medicine, found that the drug had no impact on the rate of cardiovascular mortality.
Looking for a new drug to lower LDL is a sign that quite few people have now accepted that statins do not work...but addressing CVDs from the same point of view (i.e. LDL) is the fundamental problem as described here and here.
So, are we still at square one?
I am afraid we are...as long we believe that LDL is the problem...
A novel approach is badly needed...
(an approach that we describe in the book we are writing...)
